-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ulcerative colitis (UC) is an idynogenic chronic inflammatory bowel disease (IBD), characterized by remission and recurrence.
the initial goal of UC therapy is to achieve clinical remission, advances in the current assessment of UC activity and treatment have changed UC's therapeutic goals.
In particular, recent studies have shown that the goal of IBD therapy is to achieve mucosal healing, thereby reducing hospitalization and intestinal excision, thereby improving the prognosis of UC patients, according to which the prediction of clinical recurrence is important for treatment.
role of prosaltin E-major urinary metabolites (PGE-MUM) as biomarkers for UC activity judgment has been reported.
, this study aims to explore whether PGE-MUM (a urine test that is simpler than a fecal test) can predict a recurrence of UC.
researchers conducted PGE-MUM measurements and endoscopic evaluations in 70 clinically remission UC patients.
and calculates the best threshold for predicting recurrence and recurrence-free rates.
16 patients (22.9%) relapsed during the 12-month follow-up period.
the median PGE-MUM in patients who relapsed at the time of hospitalization was significantly higher than the PGE-MUM value in clinically remission patients (P s 0.008).
based on the recipient's working characteristics (ROC) analysis, the critical value of PGE-MUM predicting future recurrence is 25.2 μg/g Cr, and the area under the ROC curve is 0.721 (95% confidence interval: 0.556-0.886).
the recurrence rate in patients with PGE-MUM≥25.2 μg/g Cr was significantly lower than that in patients with PGE-MUM and 25.2 ?g/g Cr.
ROC analysis of UC patients with a range of more than 1-8 years showed that the course of disease over 5 years was the largest at the ROC curve, with a maximum area of 0.821 (95% confidence interval: 0.583-1.000) and an optimal critical value of 26.3 ?g/g Cr.
, this trial confirms that PGE-MUM is a reliable biomarker for predicting future recurrence of UC, especially in UC patients with long disease durations.
。
